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Abstract
Background: Associations between adipokines and bone mineral density (BMD) in knee osteoarthritis (OA) remain
indistinct. The aim of this study was to investigate the cross-sectional associations between serum levels of
adipokines and BMD in patients with knee OA.
Methods: This study included 164 patients with symptomatic knee OA from the Anhui Osteoarthritis study. Serum
levels of leptin, adiponectin, and resistin were measured using an enzyme-linked immunosorbent assay (ELISA).
BMD at total body, spine, hip, and femur were measured by dual-energy X-ray absorptiometry (DXA).
Results: In multivariable analyses, serum levels of leptin were significantly associated with reduced BMD at total body,
hip, total femur, femoral neck, and femoral shaft (β = − 0.019, 95% CI -0.034 to − 0.005; β = − 0.018, 95% CI -0.034 to − 0.
003; β = − 0.018, 95% CI -0.034 to − 0.002; β = − 0.016, 95% CI -0.032 to 0.000; β = − 0.026, 95% CI -0.046 to − 0.006;
respectively). Serum levels of adiponectin were significantly and negatively associated with BMD at total femur and
femoral shaft (β = − 0.007, 95% CI -0.013 to 0.000; β = − 0.011, 95% CI -0.018 to − 0.003; respectively). However, no
significant associations were found between serum levels of resistin and BMD at any site measured.
Conclusions: Serum levels of leptin and adiponectin were significantly and negatively associated with BMD,
suggesting potentially detrimental effects of leptin and adiponectin on BMD in knee OA patients.
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Background
Osteoarthritis (OA) is the most prevalent joint disease
worldwide, characterized by gradual loss of articular
cartilage, synovial inflammation, osteophyte formation,
and other structural changes. OA affected approximately
18% of women and 10% of men aged over 60 years
according to the WHO’s report [1].
Obesity is a well-recognized risk factor for OA,
particularly in the weight-bearing joints. However,
obesity-increased joint loading could not account for the
associations between OA and non-weight-bearing joints
such as hand and shoulder joints. Recent studies consid-
ered that obesity-related metabolic inflammation might
contribute to OA [2, 3].
Adipokines, including leptin, adiponectin, and resistin
which are mostly studied, are secreted by white adipose
tissue, and have been found in synovial fluid and cartil-
age tissues obtained from OA patients [4, 5]. Leptin had
been shown to be positively associated with the severity
of OA [6, 7]; however, leptin was significantly associated
with increased knee cartilage volume in patients with
radiographic OA [8]. Another study [9] reported that
leptin was not significantly associated with cartilage
damage in OA patients. The role of adiponectin in OA
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remains inconclusive. Some studies suggested a protect-
ive effect of adiponectin in OA [8, 10, 11], while others
found no association [12, 13] or even a positive association
between serum adiponectin and disease severity in knee
OA [14]. Studies regarding correlations between resistin
and OA are sparse and have been controversial [15, 16].
The relationship between OA and bone mineral dens-
ity (BMD) has been reported in various cross-sectional
and longitudinal studies, but remains controversial. Pre-
vious studies revealed that higher BMD was associated
with an increased risk of incident OA defined by osteo-
phyte or Kellgren-Lawrence (KL) grade, suggesting that
increased BMD was a risk factor for OA [17–19], but a
recent study using MRI reported a positive association
between systemic and subchondral BMD and cartilage
thickness in patients with radiographic OA, indicating
that BMD may play a protective role in OA [20].
Given that both adipokines and BMD might be in-
volved in the etiology of OA, they would have a close re-
lationship; however, associations between adipokines and
BMD in OA are rarely reported though numerous stud-
ies reported the associations between adipokines and
BMD in healthy human which remains controversial.
One study was conducted in 60 postmenopausal women
with hip or knee OA and reported no correlation
between leptin and BMD [21]. Another study found that
whole body BMD was positively correlated with the
serum leptin level in 50 postmenopausal women with
knee OA, but the correlation disappeared after adjust-
ment for covariates [22]. To the best of our knowledge,
there were no studies reporting the associations between
adiponectin, resistin and BMD in OA patients so far.
The aim of this study, therefore, was to investigate the
cross-sectional associations between serum adipokines
levels and BMD in patients with knee OA.
Methods
Subjects
This study was part of the Anhui Osteoarthritis (AHOA)
Study, a clinical study of 205 patients aged 34-74 years,
aimed to identify the environmental and biochemical fac-
tors associated with the progression of knee OA. Patients
with clinical knee OA, diagnosed using American College
of Rheumatology criteria [23], were consecutively re-
cruited from the Department of Rheumatology and
Immunology in the First Affiliated Hospital of Anhui
Medical University, from January 2012 to November 2013.
We excluded institutionalized patients, patients with
rheumatoid arthritis or other inflammatory diseases, pa-
tients with severe OA planning to have knee arthroplasty
in 2 years, patients who did not have blood samples so the
adipokines were not able to be measured, and patients
who didn’t have BMD measured due to personal reasons.
Forty-one patients fulfilled the exclusion criteria and
therefore were excluded from this study, leaving 164 pa-
tients. The study was approved by the First Affiliated Hos-
pital Anhui Medical University ethics committee (the
ethics approval number: H1000589), and written informed
consent was obtained from all participants according to
the Declaration of Helsinki.
Anthropometrics
Weight was measured to the nearest 0.1 kg (with shoes,
socks and bulky clothing removed) by using a single pair
of electronic scales that were calibrated using a known
weight at the beginning. Height was measured to the
Table 1 Characteristics of participants (split by median level of leptin)
Total (n = 164) Leptin ≤ median (n = 82) Leptin > median (n = 82) p value
Age, yrsa 55.42(8.57) 54.57(8.94) 56.27(8.14) 0.206
Females, %b 88.4 81.7 95.1 0.015
Height, cma 158.64(6.83) 158.62(7.70) 158.66(5.90) 0.971
Weight, kga 65.07(10.29) 63.00(9.57) 67.08(10.61) 0.012
BMI, kg/m2a 25.84(3.75) 24.98(2.83) 26.68(4.32) 0.004
BMD, kg/m2
Total bodya 10,55(1.22) 10.64(1.41) 10.46(1.02) 0.361
Spinea 10.03(1.34) 10.09(1.66) 9.99(1.08) 0.709
Hipa 8.65(1.23) 8.90(1.42) 8.47(1.06) 0.060
Total femura 9.31(1.30) 9.43(1.37) 9.21(1.24) 0.283
Knee ROA, %b 71.95 78.05 65.85 0.082
Adiponectin, ug/mlc 27.09(6.80,60.88) 11.73(3.56,35.25) 49.70(20.62,74.10) < 0.001
Resistin, ng/mlc 2.22(1.40,4.55) 2.06(1.17,4.39) 2.27(1.48,4.63) 0.327
Leptin median level: 5.92 ng/ml
Data in bold denote statistically significant results
BMI body mass index, BMD bone mineral density, BMC bone mineral content, ROA radiographic osteoarthritis
at tests were used for mean (standard deviation), bx2 tests for the proportions, cMann-Whitney U tests for median (interquartile range)
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nearest 0.1 cm (with shoes, socks and headgear
removed) by using a stadiometer. Body mass index
(BMI) was calculated [weight (kg)/height (m)2].
Serum adipokines measurements
Fasting blood was obtained from all patients in the morn-
ing. Serum was separated and aliquotted into plastic stor-
age tubes. Aliquots were stored at − 80 °C till analysis.
Serum levels of leptin, adiponectin, and resistin were mea-
sured by using enzyme-linked immunosorbent assay
(ELISA; eBioscience, USA) kits, according to the manufac-
turer’s instructions. The intra- and inter-assay coefficient
of variations for leptin, adiponectin, and resistin were 5.7
and 6.9%, 4.2 and 3.1%, 5.1 and 8.1%, respectively.
BMD measurement
BMD of the total body, spine, hip and total femur, including
femoral neck, Wards triangle, greater trochanter, and
femoral shaft were measured using dual-energy x-ray
absorptiometry (DXA) (Lunar Prodigy DF + 310,504, GE
Healthcare, USA). BMD was calculated from the bone area
(cm2) and bone mineral content (g) and expressed in g/cm2
[24]. The unit of BMD was converted to kg/m2 to keep the
levels of adipokines and BMD at the similar magnitudes.
Knee radiographic assessment
A standing anteroposterior semiflexed view of the dis-
eased knee (the severer one if both were affected) with
15° of fixed knee flexion, was performed in all partici-
pants. KL grading system (grades 0-4) was used to assess
the radiographic severity of OA [25]. Radiographic OA
(ROA) was defined as KL grade of ≥2.
Statistical analysis
Student’s t tests, Mann-Whitney U tests or chi-squared
tests were used to compare means, median or propor-
tions, respectively. Univariable and multivariable linear
regression analyses were used to examine the associations
between adipokines and BMD before and after adjustment
for age, sex, BMI and ROA. Scatter plots were also used
to depict the associations between adipokines and BMD
after adjustment for the above-mentioned covariates.
Standard diagnostic checks of model fit and residuals were
routinely made, and data points with large residuals and/
or high influence were investigated for data errors. A p
value < 0.05 (two-tailed) or a 95% confidence interval (CI)
not including the null point was regarded as statistically
significant. All statistical analyses were performed using
SPSS 13.0 for Windows (SPSS, Chicago, IL, USA).
Results
A total of 164 subjects between 34 and 74 years of age
(mean, 55.4 yrs) participated in our study. Of these, all
subjects measured the BMD of total body and total femur,
however, only 133 subjects measured the BMD of spine
and hip. There were no significant differences in demo-
graphic factors (age, sex, and BMI) between these partici-
pants and those excluded (n = 41; data not shown).
Characteristics of the participants are presented in Table 1.
The mean BMI was 25.84 kg/m2. The median levels of
leptin, adiponectin, and resistin were 5.92 ng/ml, 27.09μg/
ml, and 2.22 ng/ml, respectively. Subjects with higher and
lower levels of leptin (split at the median level) were simi-
lar in age, height, BMD at all sites measured, prevalence
of ROA and levels of resistin; however, subjects with
higher leptin levels had greater proportion of females,
higher weight, higher BMI and higher adiponectin levels.
There were no interactions between serum levels of adi-
pokines and sex on the BMD (data not shown). Therefore,
males and females were combined for analyses in our study.
Associations between leptin and BMD were shown in
Table 2. In univariable analyses, we did not find any
significant associations between serum levels of leptin
and BMD at any site measured. However, after
Table 2 Associations between leptin and BMD in various regions
Univariable Multivariablea
β(95% CI) p value β(95% CI) p value
Total body BMD −0.011(− 0.026,0.004) 0.155 − 0.019(− 0.034,-0.005) 0.009
Spine BMD 0.004(− 0.013,0.021) 0.653 − 0.010(− 0.028,0.007) 0.248
Hip BMD − 0.010(− 0.025,0.006) 0.213 − 0.018(− 0.034,-0.003) 0.018
Total femur BMD − 0.007(− 0.023,0.008) 0.352 − 0.018(− 0.034,-0.002) 0.024
Femoral neck −0.010(− 0.025,0.006) 0.218 −0.016(− 0.032,0.000) 0.048
Wards triangle −0.007(− 0.025,0.011) 0.462 −0.012(− 0.029,0.006) 0.194
Greater trochanter −0.004(− 0.018,0.009) 0.538 −0.013(− 0.026,0.001) 0.074
Femoral shaft −0.008(− 0.028,0.011) 0.386 −0.026(− 0.046,-0.006) 0.012
Dependent variable: BMD in respective compartment
Independent variable: leptin
Data in bold denote statistically significant results
BMD bone mineral density, BMI body mass index, ROA radiographic osteoarthritis
aAdjusted for age, sex, BMI and ROA
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adjustment for age, sex, BMI and ROA, serum levels of
leptin were significantly associated with reduced BMD at
total body, hip, femoral neck, femoral shaft, and total
femur (Table 2, Fig. 1).
Serum adiponectin was significantly and negatively
associated with BMD at femoral shaft and total femur in
univariable analyses. These negative associations
remained unchanged after adjustment for the covariates
mentioned above (Table 3, Fig. 2). We did not find any
significant associations between serum adiponectin and
BMD at total body, spine, and hip. The association
between adiponectin and femoral neck BMD was also
negative but of borderline statistical significance
(Table 3).
The associations between serum resistin and BMD at
any site did not reach statistical significance before and
after adjustment for age, sex, BMI and ROA (Table 4).
Discussion
The present study investigated the cross-sectional asso-
ciations between adipokines (including leptin, adiponec-
tin, and resistin) and BMD in patients with knee OA.
We found that the serum leptin levels were negatively
associated with total body, hip and total femur (includ-
ing femoral neck and femoral shaft) BMD. Serum adipo-
nectin was also significantly associated with reduced
BMD at total femur and femoral shaft. In contrast, no
association was found between serum resistin and BMD.
Leptin, a protein encoded by the ob gene, was found
to regulate bone metabolism. Various studies have
demonstrated the association between leptin and BMD.
Ducy et al. [26] found that intracerebroventricular infu-
sion of leptin induced bone loss in both leptin-deficient
and wild-type mice, suggesting that leptin could inhibit
bone formation acting through the hypothalamus.
Fig. 1 Scatter plot for associations between serum levels of leptin and bone mineral density (BMD). In multivariable analyses, higher serum levels
of leptin were associated with lower BMD at total body (a) and hip (b)
Table 3 Associations between adiponectin and BMD in various regions
Univariable Multivariablea
β(95% CI) p value β(95% CI) p value
Total body BMD −0.005(− 0.010,0.000) 0.072 −0.002(− 0.007,0.003) 0.432
Spine BMD −0.006(− 0.013,0.002) 0.123 −0.002(− 0.010,0.005) 0.518
Hip BMD −0.006(− 0.012,0.001) 0.100 −0.002(− 0.009,0.004) 0.456
Total femur BMD −0.006(− 0.012,0.000) 0.034 −0.007(− 0.013,0.000) 0.030
Femoral neck −0.006(− 0.011,0.000) 0.061 −0.005(− 0.011,0.001) 0.088
Wards triangle −0.005(− 0.012,0.002) 0.137 −0.004(− 0.010,0.003) 0.234
Greater trochanter −0.004(− 0.009,0.001) 0.116 −0.002(− 0.007,0.003) 0.436
Femoral shaft −0.008(− 0.015,-0.001) 0.025 −0.011(− 0.018,-0.003) 0.006
Dependent variable: BMD in respective compartment
Independent variable: adiponectin
Data in bold denote statistically significant results
BMD bone mineral density, BMI body mass index, ROA radiographic osteoarthritis
aAdjusted for age, sex, BMI and ROA
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Epidemiological studies reported that serum leptin con-
centrations were inversely associated with calcaneal
BMD after adjustment for body weight in 221 healthy
adult men [27], and leptin had a negative correlation
with lumbar spine BMD in perimenopausal healthy
women [28]. On the contrary, some studies reported a
positive association between leptin and BMD. Martin et
al. [29] demonstrated that peripheral administration of
leptin could prevent disuse-induced bone loss through
inhibiting the increase in bone resorption mediated by
the RANKL/OPG and preventing the decrease in bone
formation in tail-suspended female rats. Blain et al. [30]
found that leptin was positively associated with whole
body and femoral neck BMD in 155 postmenopausal
women. Weiss et al. [31] reported that leptin predicted
an increase in BMD in postmenopausal women but not
older men after adjustment for age, BMI, and other bone
related factors. In addition, several clinical studies re-
ported no association between leptin and BMD or BMD
change [32, 33]. It was noteworthy that these studies
mentioned above were conducted in healthy persons.
Only two clinical studies investigated the association
between leptin and BMD in OA [21, 22] and reported
inconsistent results. Our study found that serum leptin
was significantly associated with reduced BMD in
patients with knee OA, independent of age, sex, BMI,
and ROA. This suggests that leptin may play a
potentially detrimental effect on BMD in knee OA.
Adiponectin was considered to have a negative effect
on bone metabolism. Adiponectin levels were negatively
associated with femoral neck and total body BMD in
postmenopausal women after adjustment for potential
confounders [32], and highest tertile of adiponectin had
significantly greater hip BMD loss than the lowest tertile
of adiponectin in women [33]. A meta-analysis indicated
that adiponectin was the mostly relevant adipokine that
was negatively associated with BMD in healthy subjects,
regardless of menopausal status and gender [34].
Fig. 2 Scatter plot for associations between serum levels of adiponectin and bone mineral density (BMD). In multivariable analyses, higher serum
levels of adiponectin were associated with lower BMD at total femur (a) and femoral shaft (b)
Table 4 Associations between resistin and BMD in various regions
Univariable Multivariablea
β(95% CI) p value β(95% CI) p value
Total body BMD 0.005(−0.042,0.053) 0.825 0.005(−0.037,0.048) 0.801
Spine BMD −0.022(− 0.117,0.072) 0.639 − 0.024(− 0.120,0.071) 0.612
Hip BMD − 0.005(− 0.093,0.083) 0.913 0.012(− 0.072,0.096) 0.777
Total femur BMD − 0.010(− 0.061,0.042) 0.712 −0.007(− 0.056,0.043) 0.792
Femoral neck −0.023(− 0.075,0.029) 0.376 −0.023(− 0.073,0.027) 0.358
Wards triangle −0.030(− 0.090,0.030) 0.327 −0.031(− 0.086,0.023) 0.257
Greater trochanter −0.014(− 0.059,0.031) 0.528 −0.012(− 0.054,0.030) 0.568
Femoral shaft 0.002(−0.062,0.066) 0.951 0.003(−0.061,0.067) 0.918
Dependent variable: BMD in respective compartment
Independent variable: resistin
BMD bone mineral density, BMI body mass index, ROA radiographic osteoarthritis
aAdjusted for age, sex, BMI and ROA
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Oshima et al. [35] reported that adiponectin supplement
increased bone mass in trabecular bone via inhibiting
osteoclast and activating osteoblast. In contrast, Konto-
gianni et al. [28] found no associations between adipo-
nectin and lumber spine BMD in perimenopausal
women, and Barbour et al. [33] found adiponectin levels
were not correlated with whole-body areal BMD or
trabecular lumbar spine volumetric BMD loss in older
women and men. Our current study is the first to inves-
tigate the association between adiponectin and BMD in
patients with knee OA, indicating a potentially
detrimental effect of adiponectin on BMD in knee OA.
Serum leptin levels are positively correlated with BMI,
while serum adiponectin levels are negatively correlated
with BMI [36]. However, we found that both serum
levels of leptin and adiponectin were negatively associ-
ated with BMD in OA. The potential mechanism is un-
clear, and it needs to be further investigated.
So far, there are a few studies reporting the association
between resistin and BMD. Serum resistin was not asso-
ciated with BMD of total body, lumbar spine, and total
hip before and after adjustment for age and fat mass in
232 Chinese men [37], and was not an independent pre-
dictor of BMD in 336 healthy postmenopausal Chinese
women aged 41-81 years [38]. One study reported that
serum resistin levels were significantly and negatively
associated with lumbar spine BMD in 80 middle-aged
men [39]. In our current study, we didn’t find any
significant association between serum resistin and BMD
in patients with knee OA.
There are several limitations in our study. First, due to
the cross-sectional nature, the causality between adipo-
kines and BMD is not able to be determined. Further lon-
gitudinal studies are needed to verify our findings. Second,
the sample size was modest. This may be the reason why
we did not find significant association between resistin
and BMD. Third, 41 patients were excluded from this
study which may cause selection bias; however, there were
no significant differences in age, sex, and BMI between pa-
tients who were included and excluded. Last, there would
be variations in muscle and fat mass which may affect the
associations; however, the results remained largely un-
changed after the adjustment for muscle or fat mass.
Conclusions
Serum leptin and adiponectin levels were significantly
and negatively associated with BMD, suggesting poten-
tially detrimental effects of leptin and adiponectin on
BMD in knee OA patients.
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